Nicholson, Luke
Talks, Stephen J. http://orcid.org/0000-0001-6126-6476
Amoaku, Winfried http://orcid.org/0000-0001-5028-7984
Talks, Katherine
Sivaprasad, Sobha http://orcid.org/0000-0001-8952-0659
Article History
Received: 22 December 2021
Revised: 24 January 2022
Accepted: 21 February 2022
First Online: 17 March 2022
Competing interests
: Dr. LN has received speaker fees from Allergan and Bayer. Mr SJT has attended Advisory Boards for Bayer, Novartis, Alimera and Allergan. He has participated in Pharma-sponsored Clinical Trials for Bayer, Novartis, Roche and Boehringer Ingelheim. He has also received educational travel grants from Bayer. Mr WA has received research funding from Allergan, Bayer, Bausch and Lomb, Boehringer Ingelheim, CentreVue, Novartis, Optos plc, Topcon, and Pfizer, and served on ad hoc Advisory Boards for Alcon, Allergan, Novartis, Bayer, Alimera, Roche and Thrombogenics, and has received educational travel grants from Alimera, Allergan, Bayer, Novartis and Pfizer, speaker honoraria from Alimera, Allergan, Bausch and Lomb, Bayer, Novartis and Pfizer. He has been involved with Pharma-sponsored Clinical Trials: Allergan, Bausch and Lomb, Novartis, Pfizer2009 – 14. Clinical Trials: (i) National CI (and PI, Nottingham) Pfizer. Case-Crossover Study of PDE5 Inhibitor as factor in AION; (ii) PI- Novartis. REPAIR Phase 2, Protocol CRFB002AGB10. Multicentre; (iii) PI- Novartis. COMRADE B and C. Phase 3, Protocol CRFB002 EDE17 and CRFB002 EDE18. Multicentre trial ranibizumab vrs dexamethasone in BRVO and CRVO; (iv) PI- Phase 4 Observational Constance; (v) Novartis REPAIR: Phase 2. Protocol CRFB002AGB10. PI; (vi) PI- Novartis. KESTREL Phase 3, Protocol CRTH258B2301, RTH in DMO; (vii) PI- Gyroscope CFI/SiGHt study: The Complement Factor I in AMD Study. Protocol GT005-01. He was also a member of the Macular Society Scientific Committee until 2015. Dr KT has received educational travel grants from CSL-Behring, Pfizer & Sobi. Prof SS has received an honorarium for advisory board meetings and speaker fees from Allergan, Boehringer Ingleheim, Novartis, Bayer, Optos, Heidelberg Engineering, Oxurion, Ophthea, Oculis, Apellis and Roche. Been awarded institutional research grants by Novartis, Bayer, Allergan, Boehringer Ingleheim. Received support from industry towards publication for the AURA and RELIGHT, and research grants from: Novartis, Bayer, Allergan, Boehringer Ingleheim, Optos, Opthea.
Free to read: This content has been made available to all.